27404-31-5

Basic information

• Product Name: 2-BENZO[B]FURAN-3-YLETHYLAMINE
• Synonyms: 2-BENZO[B]FURAN-3-YLETHYLAMINE;2-Benzo[b]furan-3-ylethylamine 97%;3-Benzofuranethanamine;2-(benzofuran-3-yl)ethanamine;3-(Aminoethyl)benzo[b]furan 97%;2-(1-Benzofuran-3-yl)ethylamine, 2-(Benzo[b]furan-3-yl)ethylamine, 3-(Aminoethyl)-1-benzofuran;2-(1-benzofuran-3-yl)ethan-1-aMine;2-Benzofuran-3-yl-ethylaMine
• CAS NO: 27404-31-5
• Molecular Formula: C₁₀H₁₁NO
• Molecular Weight: 161.2
• Mol File: 27404-31-5.mol
• Article Data: 15

Chemical Properties

• Melting Point: 183-185 °C
• Boiling Point: 268.529 °C at 760 mmHg
• Flash Point: 116.202 °C
• Appearance: /
• Density: 1.129 g/cm³
• Vapor Pressure: 0.008mmHg at 25°C
• Refractive Index: 1.609
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 9.71±0.10(Predicted)
• CAS DataBase Reference: 2-BENZO[B]FURAN-3-YLETHYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BENZO[B]FURAN-3-YLETHYLAMINE(27404-31-5)
• EPA Substance Registry System: 2-BENZO[B]FURAN-3-YLETHYLAMINE(27404-31-5)

Safety Data

• Hazardous Substances Data: 27404-31-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
2-Benzo[b]furan-3-ylethylamine is used as a research compound for investigating its psychoactive or central nervous system effects. Its potential role in drug discovery and medicinal chemistry makes it a valuable tool for developing new drugs targeting neurotransmitter systems in the brain.
Used in Drug Development:
In the pharmaceutical industry, 2-Benzo[b]furan-3-ylethylamine is utilized as a lead compound for the development of novel therapeutic agents. Its unique structure and potential interactions with neurotransmitter systems offer opportunities for creating innovative treatments for various neurological and psychiatric disorders.
Used in Neurotransmitter System Research:
2-BF-3-YL-EA is employed as a research tool in neuroscience to study the interactions between chemical compounds and neurotransmitter systems. Understanding these interactions can provide insights into the development of drugs that modulate neurotransmission, potentially leading to new treatments for neurological conditions.

InChI:InChI=1/C10H11NO/c11-6-5-8-7-12-10-4-2-1-3-9(8)10/h1-4,7H,5-6,11H2

Upstream product

• 27404-32-6 N-2-(benzo[b]furan-3-yl)ethylamine hydrochloride 
• 21535-97-7 3-methyl-benzofuran 
• 1878-62-2 2-(2-acetylphenoxy)acetic acid 
• 63815-27-0 2-(2'-acetylphenoxy)acetic acid ethyl ester 
• 441055-15-8 (rac)-2-acetylamino-3-benzofuran-3-yl-propionic acid 
• 1023290-69-8 2-acetylamino-2-benzofuran-3-yl-methyl-malonic acid diethyl ester 
• 118-93-4 o-hydroxyacetophenone 
• 67713-99-9 (benzofuran-3-yl)methyl chloride 
• 4687-23-4 3-hydroxymethylbenzofuran 
• 4687-25-6 1-benzofuran-3-carbaldehyde 
• 7169-34-8 3-oxo-2,3-dihydrobenzo[b]furan 
• 52407-43-9 3-cyanomethylbenzo[b]furan 

Downstream Products

• 1160484-75-2 naphthalen-2-ylmethyl2-(benzofuran-3-yl)ethylcarbamodithioate 
• 1569976-46-0 methyl 4-(1-(2-(benzofuran-3-yl)ethyl)-4-hydroxy-3-nicotinoyl-5-oxo-2,5-dihydro-1H-pyrrol-2-yl)benzoate 
• 1355024-57-5 1,5,6,11b-tetrahydro-11-oxa-2,4a-diaza-benzo[a]fluorene-2,3-dicarboxylic acid 2-tret-butyl ester 3-methyl ester 
• 1355024-76-8 1-tert-butyl 2-methyl 4-(2-(benzofuran-3-yl)ethyl)-5-hydroxy-5,6-dihydropyrazine-1,2(4H)-dicarboxylate 
• 1258502-33-8 N-(2-(benzofuran-3-yl)ethyl)-5-(3-fluorobenzyl)isoxazole-3-carboxamide 
• 1226974-85-1 ethyl 2-(2-(benzofuran-3-yl)ethylcarbamoyl)acetate 
• 1226974-80-6 methyl 2-(2-(benzofuran-3-yl)ethylcarbamoyl)acetate 

Relevant articles and documents

Substrate-Tuned Catalysis of the Radical S-Adenosyl- L -Methionine Enzyme NosL Involved in Nosiheptide Biosynthesis

NosL is a radical S-adenosyl-L-methionine (SAM) enzyme that converts L-Trp to 3-methyl-2-indolic acid, a key intermediate in the biosynthesis of a thiopeptide antibiotic nosiheptide. In this work we investigated NosL catalysis by using a series of Trp analogues as the molecular probes. Using a benzofuran substrate 2-amino-3-(benzofuran-3-yl)propanoic acid (ABPA), we clearly demonstrated that the 5′-deoxyadenosyl (dAdo) radical-mediated hydrogen abstraction in NosL catalysis is not from the indole nitrogen but likely from the amino group of L-Trp. Unexpectedly, the major product of ABPA is a decarboxylated compound, indicating that NosL was transformed to a novel decarboxylase by an unnatural substrate. Furthermore, we showed that, for the first time to our knowledge, the dAdo radical-mediated hydrogen abstraction can occur from an alcohol hydroxy group. Our study demonstrates the intriguing promiscuity of NosL catalysis and highlights the potential of engineering radical SAM enzymes for novel activities.

Azepinoindole derivatives as pharmaceutical agents

Compounds, compositions and methods for modulating the activity of receptors are provided. In particular, compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.

N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase

The invention relates to compounds of formula (I) for treating for example sexual dysfunction, wherein R1 is optionally substituted C1-6alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, hydrogen, C1-6alkoxy, —NR2 R3 or —NR4SO2R5; X is the linkage —(CH2)n— or —(CH2)q—O— (wherein Y is attached to the oxygen); wherein one or more hydrogen atoms in linkage X may be replaced independently by C1-4alkoxy; hydroxy; hydroxy(C1-3alkyl); C3-7cycloalkyl; carbocyclyl; heterocyclyl; or by C1-4alkyl optionally substituted by one or more fluoro or phenyl groups; n is 3, 4, 5, 6 or 7; and q is 2, 3, 4, 5 or 6; and Y is phenyl or pyridyl, each of which may be substituted; or two R8 groups on adjacent carbon atoms together with the interconnecting carbon atoms may form a fused optionally substituted 5- or 6-membered carbocyclic or heterocyclyic ring.

AZEPINOINDOLE AND PYRIDOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS

The present invention is directed to compounds of formula (I) and formula (II): formula (I) and (II), wherein R1-R8, A and n are as described in the description. These compounds are used in pharmaceutical compositions and methods for modulating the activity of orphan nuclear receptors.

Substituted hexahydroarylquinolizines

Certain substituted hexahydroarylquinolizines and pharmaceutically acceptable salts thereof are peripherally selective α2 -adrenoceptor antagonists. The compounds are adapted to be employed for the treatment of certain pathological disorders such as hypertension, diabetes, disorders involving platelet aggregation and the like without side effects attributable to effect on the central nervous system.

Preparation of n-formamidoyl[(s)-1-t-butoxy-3-methyl-2-amino)]1,2,3,4 tetrahydrobenzo [b]furo [2,3-c]pyridine and derivatives

The present invention is directed to an enantioselective synthesis of 1,3,4,6,7,12b(S)-hexahydro-2H-benzo[b]furo[2,3-a]quinolizin-2-one which is an intermediate in the production of the α2 -adrenergic antagonist (2R,12bS)-N-(1,3,4,6,7,12-hexahydro-2H-benzo[b]furo[2,3-a]quinolizin-2-yl)-N-methyl-2-hydroxy-ethanesulfonamide hydrochloride.

SUBSTITUTED HEXAHYDROARYLQUINOLIZINES

Certain substituted hexahydroarylquinolizines and pharmaceutically acceptable salts thereof are peripherally selective α 2-adrenoceptor antagonists. The compounds are adapted to be employed for the treatment of certain pathological disorders such as hypertension, diabetes, disorders involving platelet aggregation and the like without side effects attributable to effect on the central nervous system.

Enantioselective synthesis of 1,3,4,6,7,12b(S)-hexahydro-2H-benzo[b]furo[2,3-a]quinolizin-2-one

An enantioselective synthesis of 1,3,4,6,7,12b(S)-hexahydro-2H-benzo[b]furo[2,3-a]quinolizin-2-one provides a key intermediate for the preparation of the α2 -adrenergic antagonist (2R,12bS)-N-(1,3,4,6,7,12-hexahydro-2H-benzo[b]furo[2,3-a]quinolizin-2-yl)-N-methyl-2-hydroxyethanesulfonamide hydrochloride, useful as an anti-depressant.

Substituted benzo[b]furo- and benzo[b]thieno quinolizines

Substituted hexahydro arylquinolizines and pharmaceutically acceptable salts thereof are selective α 2 -adrenergic receptor antagonists and thereby useful as antidepressants, antihypertensives, ocular antihypertensives, antidiabetics, antiobesity and platelet aggregation inhibitors and modifiers of gastrointestinal motility.